Skip to main content

Gepirone Disease Interactions

There are 5 disease interactions with gepirone.

Major

Antidepressants (applies to gepirone) suicidality

Major Potential Hazard, Moderate plausibility. Applicable conditions: Bipolar Disorder, Depression

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older. Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide. Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes. Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider. Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

Switch to professional interaction data

Major

Gepirone (applies to gepirone) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Exposure to gepirone is increased in patients with hepatic impairment. Use of gepirone in patients with severe hepatic impairment (Child-Pugh C) is contraindicated. A dose reduction is recommended in patients with moderate hepatic impairment (Child-Pugh B). No dosage adjustment is recommended patients with mild hepatic impairment (Child-Pugh A).

Switch to professional interaction data

Major

Gepirone (applies to gepirone) QT prolongation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome, Hypokalemia, Magnesium Imbalance, Cardiovascular Disease, Heart Disease, Congestive Heart Failure, Hypothyroidism

This drug prolongs the QT interval. Use of gepirone in patients with congenital long QT syndrome is contraindicated. Treatment is also contraindicated in patients with severe hepatic impairment or in patients receiving concomitant strong CYP450 3A4 inhibitors because plasma drug concentrations may be increased in these population. Gepirone should not be initiated in patients with baseline QTc greater than 450 msec, and the dosage of gepirone should not be escalated if the QTcF is greater than 450 msec. Electrolyte abnormalities should be corrected prior to starting treatment, and then monitored during dose titration and periodically during treatment in patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia. An electrocardiogram (ECG) should be performed prior to initiating therapy, during dosage titration, and periodically during treatment. Monitor patients with ECGs more frequently if gepirone is used concomitantly with drugs known to prolong the QT interval, in patients who develop a QTc of 450 msec or greater during treatment, or in patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism. Reduce the dose of this drug when used concomitantly with moderate CYP3A4 inhibitors, as they may increase drug concentrations.

Switch to professional interaction data

Moderate

Antidepressants (applies to gepirone) mania

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bipolar Disorder

All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.

Switch to professional interaction data

Moderate

Gepirone (applies to gepirone) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patients with renal impairment may experience reduced metabolism and excretion of gepirone. The recommended dose of gepirone in patients with CrCl less than 50 mL/min is reduced as compared to patients with normal renal function. No dosage adjustment is recommended for patients with CrCl 50 mL/min or greater.

Switch to professional interaction data

Gepirone drug interactions

There are 478 drug interactions with gepirone.

Gepirone alcohol/food interactions

There is 1 alcohol/food interaction with gepirone.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.